文献速递肝病

辛伐他汀可预防肝硬化伴门脉高压大鼠的慢加急性肝衰竭进展

Simvastatin Prevents Progression of Acute on Chronic Liver Failure in Rats With Cirrhosis and Portal Hypertension.
PubMed 文献 · Gastroenterology · 2018-07-25

研究建立脓毒症相关慢加急性肝衰竭(ACLF)临床前大鼠模型,发现脂多糖(LPS)加重肝硬化大鼠门脉高压、肝内微血管功能障碍、炎症与氧化应激并缩短生存时间;辛伐他汀可预防多数ACLF相关并发症、延长生存时间并降低转氨酶、总胆红素、血氨水平及LPS介导的肝星状细胞活化。

要点

  • LPS诱导的ACLF大鼠模型显示门脉高压加重、肝内微血管功能障碍及炎症氧化应激增加。
  • 辛伐他汀可预防多数ACLF相关并发症并延长肝硬化大鼠生存时间。
  • 辛伐他汀降低转氨酶、总胆红素、血氨水平及LPS介导的肝星状细胞活化。

核心结论

  • 在大鼠肝硬化研究中,LPS给药促进ACLF发生,加重慢性肝病并发症并缩短生存时间。
  • 辛伐他汀减少ACLF大鼠LPS诱导的炎症和肝损伤,支持其用于晚期慢性肝病患者的治疗。

研究设计与样本

  • 雄性Wistar大鼠吸入四氯化碳至10周形成肝硬化或15-16周形成肝硬化伴腹水。
  • 雄性Sprague-Dawley大鼠行胆管结扎28天或腹腔注射硫代乙酰胺10周诱导肝硬化。
  • 肝硬化诱导后部分大鼠单次注射LPS诱导ACLF,部分在ACLF诱导前4小时或24小时给予辛伐他汀或溶媒对照。
  • 收集肝脏和全身血流动力学、肝微血管表型与功能及生存时间数据,并用免疫印迹、定量聚合酶链反应、免疫(荧光)组化及免疫分析检测肝组织和血浆。

主要发现

  • LPS加重肝硬化大鼠门脉高压,机制包括增加肝内微血管功能障碍严重程度、加重肝脏炎症、增加氧化应激及招募肝星状细胞和中性粒细胞。
  • 接受LPS的肝硬化大鼠生存时间显著短于接受对照的肝硬化大鼠。
  • 辛伐他汀预防多数ACLF相关并发症并延长生存时间。
  • 辛伐他汀似可增加肝窦功能并降低门脉高压及炎症和氧化标志物。
  • 辛伐他汀显著降低肝硬化大鼠肝组织中转氨酶、总胆红素和血氨水平以及LPS介导的肝星状细胞活化。

临床怎么用

  • 作者认为,辛伐他汀减少ACLF大鼠LPS诱导的炎症和肝损伤,支持其用于晚期慢性肝病患者治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Cirrhosis and its clinical consequences can be aggravated by bacterial infections, ultimately leading to the development of acute on chronic liver failure (ACLF), characterized by acute decompensation, organ failure, and high mortality within 28 days. Little is known about cellular and molecular mechanisms of ACLF in patients with cirrhosis, so no therapeutic options are available. We developed a sepsis-associated preclinical model of ACLF to facilitate studies of pathogenesis and evaluate the protective effects of simvastatin. METHODS: Male Wistar rats inhaled CCl4 until they developed cirrhosis (at 10 weeks) or cirrhosis with ascites (at 15-16 weeks). Male Sprague-Dawley rats received bile-duct ligation for 28 days or intraperitoneal thioacetamide for 10 weeks to induce cirrhosis. After induction of cirrhosis, some rats received a single injection of lipopolysaccharide (LPS) to induce ACLF; some were given simvastatin or vehicle (control) 4 hours or 24 hours before induction of ACLF. We collected data on changes in hepatic and systemic hemodynamics, hepatic microvascular phenotype and function, and survival times. Liver tissues and plasma were collected and analyzed by immunoblots, quantitative polymerase chain reaction, immuno(fluoro)histochemistry and immunoassays. RESULTS: Administration of LPS aggravated portal hypertension in rats with cirrhosis by increasing the severity of intrahepatic microvascular dysfunction, exacerbating hepatic inflammation, increasing oxidative stress, and recruiting hepatic stellate cells and neutrophils. Rats with cirrhosis given LPS had significantly shorter survival times than rats with cirrhosis given the control. Simvastatin prevented most of ACLF-derived complications and increased survival times. Simvastatin appeared to increase hepatic sinusoidal function and reduce portal hypertension and markers of inflammation and oxidation. The drug significantly reduced levels of transaminases, total bilirubin, and ammonia, as well as LPS-mediated activation of hepatic stellate cells in liver tissues of rats with cirrhosis. CONCLUSIONS: In studies of rats with cirrhosis, we found administration of LPS to promote development of ACLF, aggravating the complications of chronic liver disease and decreasing survival times. Simvastatin reduced LPS-induced inflammation and liver damage in rats with ACLF, supporting its use in treatment of patients with advanced chronic liver disease.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Tripathi DM, Vilaseca M, Lafoz E, et al. Simvastatin Prevents Progression of Acute on Chronic Liver Failure in Rats With Cirrhosis and Portal Hypertension. Gastroenterology. 2018. PMID: 30055171. doi:10.1053/j.gastro.2018.07.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。